Ipsen
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
| Company type | Public |
|---|---|
Traded as | Euronext Paris: IPN
CAC Mid 60 Component |
| ISIN | FR0010259150 |
| Industry | Pharmaceutical |
| Founded | 1929 |
| Founder | Henri Beaufour |
| Headquarters | Boulogne-Billancourt, France |
Key people | Marc de Garidel (Non-executive Chairman) David Loew (Chief Executive Officer) |
| Products | List of medicines |
| Revenue | €2.87 billion (2021) |
| €1.01 billion (2021) | |
Net income | 610,500,000 Euro (2020) |
Number of employees | 5,700 |
| Website | www.ipsen.com |
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005),. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.